Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human

Phase 1

Not yet recruiting

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: HRS-1780 tablets; Drug: HR20033 tablets; Drug: HRS-7535 tablets

• Registration Number: NCT06495931
• Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.

Brief Summary

This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-07
• Study Start: 2024-07
• Study First Submitted: 2024-07-03
• Study First Submitted QC: 2024-07-03
• Last Update Submitted: 2024-07-03
• Study First Posted: 2024-07-11
• Last Update Posted: 2024-07-11
• Primary Completion: 2024-07-31
• Study Completion: 2024-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

1. Voluntarily sign informed consent before the start of activities related to this experiment, be able to communicate well with the investigators, understand the procedures and methods of this experiment, and be willing to strictly follow the clinical trial protocol to complete this experiment;
2. Healthy male aged 18-50 years old (including both ends of the value, subject to the signing of the informed consent);
3. Weight ≥ 50 kg, and body mass index (BMI): 22~26 kg/m2 (including both ends of the value);
4. Signed informed consent to have no birth plan for 6 months after the last dose, and agreed to take effective contraceptive measures.

Exclusion Criteria

1. Have a history of drug or food allergy, or are allergic;
2. inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting the administration and absorption of drugs;
3. QTcF > 450 ms was detected by 12-lead electrocardiogram during screening or there were other abnormalities that were clinically significant as determined by the investigator;
4. Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, syphilis antibody test positive;
5. Those who smoked more than 5 cigarettes per day in the 3 months prior to screening and could not stop using any tobacco products during the test
6. Regular drinkers in the 6 months prior to screening, i.e. those who drink more than 14 units of alcohol per week (1 unit = 285 mL for beer, or 25 mL for spirits, or 100 mL for wine) and cannot stop using any alcohol-containing products during the test period, who test positive for alcohol breath test;
7. Patients with a history of drug abuse, drug dependence (consultation) or positive urine drug abuse screening before drug administration;
8. Patients who have received any surgery within 6 months before screening;
9. Participants who have participated in clinical trials of any drug or medical device within 3 months prior to screening (subject to receiving experimental drugs or medical device intervention);
10. Blood donation (or blood loss) and blood donation (or blood loss) ≥ 400 mL within 3 months before screening, or receiving blood transfusion;
11. Patients who had any clinically significant acute disease within 1 month before screening;
12. People who have taken any prescription, over-the-counter, Chinese herbal or health product within 14 days prior to taking the study drug, and plan to take any drug or health product other than the study drug during the trial;
13. Patients with a history of severe hypoglycemia;
14. People with a history of recurrent urinary tract infections, diabetes insipidus or/and genital fungal infections;
15. Prior to screening, gastrointestinal surgery that can lead to malabsorption, or long-term use of drugs that have a direct effect on gastrointestinal motility. Have undergone bariatric surgery or procedures (such as gastric banding), or have used drugs with weight reduction effects (including but not limited to orlistat) in the 3 months prior to administration, or have experienced a weight change of more than 10% in the 3 months prior to administration;
16. Use of drugs that may affect glucose metabolism (e.g. systemic steroids, non-selective beta-blockers, monoamine oxidase inhibitors) or/and exposure to metformin and/or SGLT2 inhibitors within 1 month prior to screening;
17. Previous history of clinical gastric emptance abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcers);
18. Previous history or family history of medullary thyroid cancer, multiple endocrine adenomatosis type 2, previous history of pancreatitis or symptomatic gallbladder disease;
19. 48 h before the first dose until the end of the study, subjects refused to stop drinking or eating foods with high methylxanthine content, such as coffee, tea, cola, chocolate, etc.; For 7 days prior to the first dose until the end of the study, subjects refused to discontinue any beverage or food containing grapefruit; Those who have special dietary requirements and cannot comply with a unified diet;
20. Physical examination, vital signs, laboratory examination, abdominal ultrasound, chest film and other abnormal and clinically significant examination results;
21. Persons who have been vaccinated within 1 month prior to screening or plan to be vaccinated during the trial period;
22. Subjects with other factors deemed unsuitable for participation in the study by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment group A: HRS-1780 tablets、HR20033 tablets、HRS-7535 tablets	HRS-1780 tablets	-
Treatment group A: HRS-1780 tablets、HR20033 tablets、HRS-7535 tablets	HR20033 tablets	-
Treatment group A: HRS-1780 tablets、HR20033 tablets、HRS-7535 tablets	HRS-7535 tablets	-

Primary Outcome Measures

Name	Time	Method
PK parameters：Cmax	0 hour to 24 hours after the last dosing
PK parameters：AUC0-t	0 hour to 24 hours after the last dosing
PK parameters：AUC0-∞	0 hour to 24 hours after the last dosing

Secondary Outcome Measures

Name	Time	Method
PK parameters：Tmax	0 hour to 24 hours after the last dosing
PK parameters： t1/2	0 hour to 24 hours after the last dosing
PK parameters： CL/F	0 hour to 24 hours after the last dosing
PK parameters： Vz/F	0 hour to 24 hours after the last dosing
Incidence and severity of adverse events (AEs)	from screening to 24 hours after the last dosing

Trial Locations

Locations (1)

Xuanwu Hospital ,Capital Medical University; 🇨🇳 Beijing, Beijing, China